Description: Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. The company is based in Toronto, Canada, with U.S. offices in Southern California.
Home Page: www.edesabiotech.com
EDSA Technical Analysis
100 Spy Court
Markham,
ON
L3R 5H6
Canada
Phone:
289-800-9600
Officers
| Name | Title |
|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | CEO, Company Sec. & Director |
| Dr. Michael J. Brooks M.B.A., Ph.D. | Pres |
| Ms. Kathi Niffenegger CPA, CPA | Chief Financial Officer |
| Mr. Gary Koppenjan | VP of Investor Relations & Communications |
| Mr. Rajan Puri | Sr. VP of Manufacturing |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0.1716 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4224 |
| Price-to-Sales TTM: | 120477.9295 |
| IPO Date: | 2015-11-05 |
| Fiscal Year End: | September |
| Full Time Employees: | 16 |